Abstract: In general, one aspect disclosed features a scleral contact lens for an eye of a patient, the scleral contact lens comprising: an anterior surface; and a posterior surface, the posterior surface comprising: a central optic zone defined by a base curve according to an apical radius of the cornea of the eye; a peripheral corneal zone peripheral to the central optic zone, a clearance control zone peripheral to the optic zone, and a scleral landing zone peripheral to the clearance control zone, the scleral landing zone having a single surface shape.

Abstract: A contact lens for treating myopia of an eye of a patient comprises an anterior surface; and a posterior surface having a semi-meridian defining: a central compression zone to contact the pretreatment cornea, a volume control zone peripheral to the central compression zone, a secondary compression zone to contact the pretreatment cornea, wherein the secondary compression zone is peripheral to the volume control zone, a peripheral relief zone peripheral to the secondary compression zone, a landing zone to contact the pretreatment cornea, wherein the landing zone is peripheral to the peripheral relief zone, and an edge terminus peripheral to the landing zone.

Abstract: A chimeric lysozyme variant has an improved heat resistance and is encoded by a polynucleotide. A novel chimeric lysozyme sequence is constructed, and high-efficiency expression in a host cell is achieved. The thermal stability of the chimeric lysozyme under the condition of 60° C. is nearly doubled compared to a parental sequence. The chimeric lysozyme variant can be used to prepare product that is antibiotic, for example, animal feed additive containing the chimeric lysozyme variant and an animal feed containing the animal feed additive.

Abstract: In general, one aspect disclosed features a lens comprising: a central zone having an optical center corresponding to the visual axis of an eye of a patient; and a peripheral zone peripheral to the central zone and comprising: a first zone having a first thickness, and a second zone having a second thickness, wherein: the second thickness varies from the first thickness, and a distance from the second zone to the optical center of the central zone is selected to generate pincushion distortion or barrel distortion in the eye of the patient.

Abstract: In general, one aspect disclosed features a flexible lens element for application to a spectacle lens, the flexible lens element comprising: a central zone having an optical center corresponding to the visual axis of an eye of a patient; and a peripheral zone peripheral to the central zone and comprising: a first zone having a first thickness, and a second zone having a second thickness, wherein: the second thickness varies from the first thickness, and a distance from the second zone to the optical center of the central zone is selected to generate pincushion distortion or barrel distortion in the eye of the patient.

Abstract: A contact lens for treating myopia of an eye of a patient comprises an anterior surface; and a posterior surface having a semi-meridian defining: a central compression zone to contact the pretreatment cornea, a volume control zone peripheral to the central compression zone, a secondary compression zone to contact the pretreatment cornea, wherein the secondary compression zone is peripheral to the volume control zone, a peripheral relief zone peripheral to the secondary compression zone, a landing zone to contact the pretreatment cornea, wherein the landing zone is peripheral to the peripheral relief zone, and an edge terminus peripheral to the landing zone.

Abstract: In general, one aspect disclosed features a flexible lens element for application to a spectacle lens, the flexible lens element comprising: a central zone having an optical center corresponding to the visual axis of an eye of a patient; and a peripheral zone peripheral to the central zone and comprising: a first zone having a first thickness, and a second zone having a second thickness, wherein: the second thickness varies from the first thickness, and a distance from the second zone to the optical center of the central zone is selected to generate pincushion distortion or barrel distortion in the eye of the patient.

Abstract: In general, one aspect disclosed features a flexible lens element for application to a spectacle lens, the flexible lens element comprising: a central zone having an optical center corresponding to the visual axis of an eye of a patient; and a peripheral zone peripheral to the central zone and comprising: a first zone having a first thickness, and a second zone having a second thickness, wherein: the second thickness varies from the first thickness, and a distance from the second zone to the optical center of the central zone is selected to generate pincushion distortion or barrel distortion in the eye of the patient.

Abstract: A contact lens for treating myopia of an eye of a patient comprises an anterior surface; and a posterior surface having a semi-meridian defining: a central compression zone to contact the pretreatment cornea, a volume control zone peripheral to the central compression zone, a secondary compression zone to contact the pretreatment cornea, wherein the secondary compression zone is peripheral to the volume control zone, a peripheral relief zone peripheral to the secondary compression zone, a landing zone to contact the pretreatment cornea, wherein the landing zone is peripheral to the peripheral relief zone, and an edge terminus peripheral to the landing zone.

Abstract: In general, one aspect disclosed features a scleral contact lens for an eye of a patient, the scleral contact lens comprising: an anterior surface; and a posterior surface, the posterior surface comprising: a central optic zone defined by a base curve according to an apical radius of the cornea of the eye; a peripheral corneal zone peripheral to the central optic zone, a clearance control zone peripheral to the optic zone, and a scleral landing zone peripheral to the clearance control zone, the scleral landing zone having a single surface shape.

Abstract: A contact lens for treating myopia of an eye of a patient comprises an anterior surface; and a posterior surface having a semi-meridian defining: a central compression zone to contact the pretreatment cornea, a volume control zone peripheral to the central compression zone, a secondary compression zone to contact the pretreatment cornea, wherein the secondary compression zone is peripheral to the volume control zone, a peripheral relief zone peripheral to the secondary compression zone, a landing zone to contact the pretreatment cornea, wherein the landing zone is peripheral to the peripheral relief zone, and an edge terminus peripheral to the landing zone.

Abstract: The application provides a method for improving the stability of a low-concentration atropine ophthalmic preparation, characterized by controlling the content of the total impurity ?0.25% and/or a single impurity content of ?0.05%, as well as a method for preparing the ophthalmic preparation, an atropine ophthalmic preparation prepared therefrom and use thereof in the manufacture of a medicament for preventing and/or treating vision defects.

Abstract: The present invention belongs to the field of medicine and relates to a pharmaceutical composition for preventing and treating NITM and a medical use thereof. Specifically, the pharmaceutical composition is an ophthalmic pharmaceutical composition such as an ophthalmic preparation. Specifically, the present invention relates to a pharmaceutical composition comprising 0.001% to 0.2% of atropine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients; wherein the pH value of the pharmaceutical composition is of 4.0 to 6.5; the pharmaceutical composition comprises 0.5% to 5% of a pH adjusting agent, and the pH adjusting agent is any one or more selected from sodium dihydrogen phosphate, disodium hydrogen phosphate, citric acid, citrate, boric acid and borates. The pharmaceutical composition of the present invention can effectively treat and/or prevent NITM, and thus has a good application prospect.

Abstract: The present invention relates to an ophthalmic pharmaceutical composition, comprising 0.06 to 40 parts by weight of a solid matrix, 0.

Abstract: An electromagnetic relay is provided. The electromagnetic relay includes a first port and a second port, a first coil and a second coil, a movable armature coupled between the first port and the second port constructed to connect and disconnect the first port and the second port, a switch circuit, and a coil control circuit. The switch circuit is constructed to connect the first coil to an external power source to induce the first coil to create a first magnetic field having a first direction and disconnect the first coil from the external power source to cause the first magnetic field to collapse. The coil control circuit is constructed to induce the second coil to create a second magnetic field having a second direction responsive to the switch circuit being in the second state, the second direction being opposite the first direction.

Abstract: A system and corresponding method are provided for multi-factor biometric authentication. The system and method includes detecting a series of biometric signals with a sensor, accessing a predefined series of biometric signals from a storage device, and comparing the detected series of biometric signals to the predefined series of biometric signals with an authentication processor. On a match of the detected and predefined biometric signals, an authentication signal is transmitted by the authentication processor.

Abstract: An electromagnetic relay is provided. The electromagnetic relay includes a first port and a second port, a first coil and a second coil, a movable armature coupled between the first port and the second port constructed to connect and disconnect the first port and the second port, a switch circuit, and a coil control circuit. The switch circuit is constructed to connect the first coil to an external power source to induce the first coil to create a first magnetic field having a first direction and disconnect the first coil from the external power source to cause the first magnetic field to collapse. The coil control circuit is constructed to induce the second coil to create a second magnetic field having a second direction responsive to the switch circuit being in the second state, the second direction being opposite the first direction.

Abstract: An ophthalmic gel of gatifloxacin and the preparation method thereof are disclosed. The gel comprises gatifloxacin or its pharmaceutical salts, matrix and water. Said matrix is one or more selected from carbomer, mixture of carbomer and HPMC, and sodium hyaluronate.

Abstract: The system includes a robot body and a main robot control platform. The robot body includes a mechanical part and an electrical control part. The mechanical part includes a horizontal moving unit, an objective carrying platform unit and a bearing unit which are arranged in X, Y and Z cartesian coordinate directions. The objective carrying platform unit includes an objective carrying platform and a battery drive mechanism arranged on the objective carrying platform. A battery pushing mechanism is arranged on the battery drive mechanism. The electrical control part includes a data collection device connected with a main control computer system, a power drive mechanism, an I/O model and a wireless communication model I. The wireless communication model I, the wireless communication model II of a control backend and the wireless communication model III in the remote control device wirelessly communicate with each other.

Abstract: Provided are bromfenac organic salts and preparation method, composition and use thereof. The bromfenac organic salt has the structure as shown in the following Formula I, wherein A represents an organic base. Also provided are a method for the preparation of the bromfenac organic salt, a composition comprising the bromfenac organic salts, a use of the bromfenac organic salts or the composition thereof in manufacture of a medicament for treatment and/or prophylaxis of an inflammation or for analgesia, and a method for treatment and/or prophylaxis of an inflammation or for analgesia.